Parameter
| Biomarker | UNC93B1 | Full name | Unc-93 Homolog B1 | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Prognosis, therapeutic targets | ||
| Disease | Acute Myeloid Leukemia (AML) | Disease Subtypes | / | ||
| Organ | Blood, bone marrow | Test Sample / Technology Platform | Bone marrow (qRT-PCR, RNA sequencing) | ||
| Pathobiological Mechanisms | High expression of enriched innate immunity and metabolic pathways, negatively correlated with BCL2 leading to venetoclax resistance. | ||||
| Clinical Availability Status | Research validation: Multi-cohort validation (TCGA/GTEx/GEO), line graph concordance index 0.729. | ||||
| Notes and Dynamics | MCL-1 inhibitors can overcome the drug resistance mediated by MCL-1 and interact with hub genes such as S100A9. | ||||